Published in 2013 – EMJ Oncol. 2013;1:68-74.
Authors: Peter Kern, Mahdi Rezai, Christian Singer, Rainer Kimmig
The aim of this review is to evaluate the incorporation of genomic testing in international guidelines (North American and European) in different clinical settings. Based on this review, it seems that North American and some European countries have initiated a shift towards a more personalised medicine approach with multigene assays included in guidelines. This review covers several multi Gene assays including MammaPrint®, Oncotype DX®, Endopredict®, and PAM50.
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.